Literature DB >> 18486447

Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting.

Eleanor M Pullenayegum1, Catherine Lam, Cedric Manlhiot, Brian M Feldman.   

Abstract

OBJECTIVES: Marginal structural models (MSMs) are an increasingly popular framework in which observational data are reweighted to draw causal inferences. The ability of an MSM to accomplish this rests crucially on treatment being unconfounded by covariates in the inverse probability-of-treatment weighted data set. This paper discusses how this important property of the weights can be evaluated when both the treatment and the covariates are time dependent. Often treatment effect estimates will be sensitive to the choice of weights. A framework within which to explore reasons for this sensitivity and to select a good weighting scheme is suggested. STUDY DESIGN AND
SETTING: The methods are illustrated using an observational study of intravenous immunoglobulin for the treatment of juvenile dermatomyositis.
RESULTS: Using traditional methods for fitting the probability-of-treatment model leaves important associations between treatment and covariates. Augmenting the probability-of-treatment model accordingly both reduces the confounding and alters the treatment effect estimate.
CONCLUSIONS: Traditional model-fitting strategies for the probability-of-treatment model may leave important associations between treatment and covariates in the reweighted data set. The framework described in this article can help both to detect this and to formulate a better probability-of-treatment model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18486447     DOI: 10.1016/j.jclinepi.2007.10.024

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  3 in total

Review 1.  Juvenile dermatomyositis.

Authors:  Michelle Batthish; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 2.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

3.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference.

Authors:  Adam M Huber; Edward H Giannini; Suzanne L Bowyer; Susan Kim; Bianca Lang; Carol B Lindsley; Lauren M Pachman; Clarissa Pilkington; Ann M Reed; Robert M Rennebohm; Lisa G Rider; Carol A Wallace; Brian M Feldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-02       Impact factor: 4.794

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.